Yes Managed decline is an excellent description. It's all by design. If you're planning to implement a global new world order, first you have to destroy the old one. Ex Malaysian prime minister Mahathir Mohamad did a superb speech back in 2015 outlining this whole multi generational plan, it seems they have managed to move things forward quite dramatically in the last decade! |
 UBS upgraded AstraZeneca from 'neutral' to 'buy' on Thursday, citing the pharmaceutical firm's "sector-leading" drug pipeline.UBS noted that AstraZeneca had scored second among global pharma peers, based on the Swiss bank's analysis of six strategic parameters."We see significant upside from in-market growth drivers and the broadest late-stage pipeline among its peers," said UBS. "We see recent quantification on the potential liability from China importation investigation as a meaningful step to resolution of investor concerns."UBS also noted that AstraZeneca's current valuation of roughly 14.7x the company's core 2026 estimated price-to-earnings ratio reflected a 12% premium relative to peers. UBS has a 12-month price target for the stock of 14,200.0p."This is justified in our view by the superior growth and above-sector research and development productivity at AstraZeneca," it argued. "We see new Phase III from seven new drugs and multiple large life cycle management opportunities as key drivers of outperformance in 2025/26." |
UBS RAISES ASTRAZENECA TO 'BUY' (NEUTRAL) - PRICE TARGET 14200 (11500) PENCE |
Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating and 14,5000p target price, recommending investors to build positions at a "compelling entry point".
The bank hailed AstraZeneca as an "innovation leader", saying that the company has an underappreciated pipeline with exposure to high-value markets across oncology, cardiovascular/renal and next-generation immuno-oncology.
"With pivotal clinical data starting in 2025+, success across these markets, could start to unlock value closer to our bull case valuation, £160/share," Morgan Stanley said. That compares with Tuesday's closing price of 11,624p.
As for the near term, 2025 should be a "catalyst-rich year", delivering double-digit bottom-line growth alongside continued strong product sales momentum, the bank said.
On Morgan Stanley's estimates, the stock trades at 15 times estimated earnings for 2025. While this is a 30% premium to other large-cap pharma peers, it is "justifiable given the superior top-line driven growth outlook [...] and significantly greater pipeline optionality," the bank said. |
Morgan Stanley overweight @ £145.Looking good. |
Trump has a plan for US business that is the diametric opposite of that being instituted by the UK labour government.In making America great again,the corollary is that competing countries will be poorer.The speed with which the UK labour government has formulated an environment so similar to the 1970s is breathtaking.This time round,there is no redemption to be found in N Sea oil or a public sector paring exercise as undertaken by Thatcher.The NHS near guarantees systemic overspend.Basically,we're stuffed in this country. |
The president's plan to lower levies on US businesses risks drawing investment away from Britain, warns the Prosperity Institute. If Mr Trump cuts US corporation tax to 14 per cent, American investment in the UK could quickly dry up. The president's corporate tax plans could adversely affect Britain, where the levy on business remains at a relatively high 25 per cent. |
China doesn't look a problem which is a relief.
Suet |
There's enough in prospect to recommend AZN as a core holding in a UK equity portfolio.Revenue forecast to grow high single digits and core eps low double digits.The China situation re the authorities investigations seems manageable. "This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80 billion Total Revenue by the end of the decade. In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines." |
Great results for the year. Uptick in dividend most welcome.Should make for a positive opening. |
The loons are in charge of the asylum for sure. As they have been for a while as the last lot were as incompetent.
We've seen a dearth of a political class/civil service that puts Britain's best interests first for decades now imo.
All about managed decline, no attempts to turn the ship around by trying something different. |
Wskill
"I have never seen a more incompetent government ever in the UK what have we done to deserve this"
We've allowed the LEFT to march through the institutions, to brainwash several generations to think "with their feelings" rather than rationally and objectively is why.
We are in this mess because the political class has betrayed the British people since the 90s, as a larger and laerger segment of its populace believe "Socialism/Communism" works and want to give it a go....
because this time it will be the right kind of socialism/communism!!!!! |
The UK has no facilities to prepare and bottle vaccines surely these twits remember the fracas of the last covid troubles ,when it had to be sent to Belgium for bottling doses .Do they not know we have left the EU .
With electricity prices 4 x the USA with all this green stupidity what company will start a manufacturing business here ,even when a UK company tries this bunch of fools makes it impossible.
I have never seen a more incompetent government ever in the UK what have we done to deserve this. |
Think it's a good move. Just rolling over and accepting the new terms would leave a bad impression. |
Madness when Miliband can give £11.6 billion to African for the climate crisis we cannot support jobs for the UK more destruction of UK business by this poor effort of a government. |
Following discussions with the current government, we (AZN) are no longer pursuing our planned investment at Speke. Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous governments proposal. |
In the bin. Spamming multiple boards. |
In today's fool....https://www.fool.co.uk/2025/01/15/3-key-reasons-why-astrazenecas-share-price-looks-a-steal-to-me-right-now/ |
Selkirk,
It's beyond farce in the US litigation side. And it gets worse depending on the State one is in. |
GeckoAgree, if that was the case, I'd be claiming, at least, a million £££ back, over the years, lol. It's the US... If they can find blame, it's a claim. Surely there's no mileage in this. |
AZN INVESTOR DEADLINE: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jan 13 2025 14:15 GMT
SAN DIEGO , Jan. 13, 2025 /PRNewswire/
--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZenecaclass action lawsuit.
Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZenecaclass action lawsuit charges AstraZeneca as well as certain of AstraZeneca's top executives with violations of the Securities Exchange Act of 1934. |
What is today's news?
Cant see anything Astra Zeneca specific. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
